Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis ; volume:6 ; number:4 ; day:18 ; month:10 ; year:2019 ; pages:611-616 ; date:12.2019
Rheumatology and therapy ; 6, Heft 4 (18.10.2019), 611-616, 12.2019
- Creator
-
Park, Siyeon
Le, Tham T.
Slejko, Julia F.
Villalonga-Olives, Ester
Onukwugha, Eberechukwu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-019-00175-6
- URN
-
urn:nbn:de:101:1-2020031405484201912489
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Park, Siyeon
- Le, Tham T.
- Slejko, Julia F.
- Villalonga-Olives, Ester
- Onukwugha, Eberechukwu
- SpringerLink (Online service)
Other Objects (12)
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States
High-dose opioid utilization and mortality among individuals initiating hemodialysis
Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis
Predictors of tumor necrosis factor inhibitors primary failure in rheumatoid arthritis patients
Validation of rheumatoid arthritis diagnoses in health care utilization data
Estimation of optimal adherence threshold for tumor necrosis factor inhibitors in rheumatoid arthritis
Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule
Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
Stages of use: consideration, initiation, utilization, and outcomes of an internet-mediated intervention
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States
High-dose opioid utilization and mortality among individuals initiating hemodialysis
Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis
Predictors of tumor necrosis factor inhibitors primary failure in rheumatoid arthritis patients
Validation of rheumatoid arthritis diagnoses in health care utilization data
Estimation of optimal adherence threshold for tumor necrosis factor inhibitors in rheumatoid arthritis
Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule
Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
Stages of use: consideration, initiation, utilization, and outcomes of an internet-mediated intervention
Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States
High-dose opioid utilization and mortality among individuals initiating hemodialysis
Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis
Predictors of tumor necrosis factor inhibitors primary failure in rheumatoid arthritis patients
Validation of rheumatoid arthritis diagnoses in health care utilization data
Estimation of optimal adherence threshold for tumor necrosis factor inhibitors in rheumatoid arthritis
Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule
Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis